首页> 外文期刊>Journal of Clinical Oncology >Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
【24h】

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

机译:染色体臂1p和19q的改变可预测少突胶质细胞瘤,星形细胞瘤和混合性少突星形细胞瘤的存活。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. RESULTS: The oligodendroglial phenotype was highly associated with loss of 1p (P =.0002), loss of 19q (P <.0001), and combined loss of 1p and 19q (P <.0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P =.03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P <.01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. CONCLUSION: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.
机译:目的:最近的报告表明,在接受卡巴肼,洛莫斯汀和长春新碱化学疗法治疗的间变性少突胶质细胞瘤患者中,染色体臂1p和19q的改变与化疗反应和总体存活率有关。我们着手进一步阐明这些改变在更广泛的弥散性神经胶质瘤(包括星形细胞肿瘤和低度少突胶质神经胶质瘤)中的诊断和预后意义。患者和方法:在正在进行的前瞻性研究中收集了162个弥漫性神经胶质瘤(79个星形细胞瘤,52个少突胶质细胞瘤和31个混合少突星形胶质细胞瘤)中的DNA探针映射到1p和19q常见缺失区域的荧光原位杂交(FISH)信号。中枢神经系统肿瘤。结果:少突神经胶质表型与1p丢失(P = .0002),19q丢失(P <.0001)以及1p和19q组合丢失(P <.0001)高度相关。 1p和19q的联合损失被确定为纯少突胶质细胞瘤患者总体生存时间延长的单因素预测因素(log-rank,P = .03),并且在调整了患者年龄和肿瘤分级的影响后,仍然是重要的预测因素(P < .01)。这种有利的联系在星形细胞瘤或混合性少星形细胞瘤患者中并不明显。结论:1p和19q的联合丧失是纯少突胶质细胞瘤患者延长生存的统计学显着预测指标,与肿瘤等级无关。鉴于星形细胞肿瘤患者缺乏这种关联,并且先前已证明少突胶质细胞瘤的化学敏感性,组织学和基因型评估相结合的方法可能会改善现有的患者分层和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号